✦ LIBER ✦

An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin

✍ Scribed by R. Goel; E. Chouinard; D. J. Stewart; S. Huan; H. Hirte; S. Stafford; B. Waterfield; J. Roach; C. Lathia; V. Agarwal; R. Humphrey; W. Walsh; S. Matthews; L. Seymour

Book ID: 111579938
Publisher: Springer US
Year: 2005
Tongue: English
Weight: 86 KB
Volume: 23
Category: Article
ISSN: 0167-6997
DOI: 10.1023/b:drug.0000047107.35764.d9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

NCIC CTG IND 113: two phase I dose escal

NCIC CTG IND 113: two phase I dose escalation pharmacokinetic (PK) studies of BAY 12-9566 (BAY) in combination with either doxorubicin (DOX) or modulated 5-fluorouracil (FU)

✍ Hirte, H.; Stewart, D.; Goel, R.; Chouinard, E.; Huan, S.; Elias, I.; Matthews, 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Phase I study of the thrombospondin-1-mi

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination

✍ R. Hoekstra; F.Y.F.L. de Vos; F.A.L.M. Eskens; E.G.E. de Vries; D.R.A. Uges; R. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 144 KB